MedTrace Logo

Quantification of Tenofovir Alafenamide Adherence (QUANTI-TAF)

NCT04065347 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2024-08-27

No results posted yet for this study

Summary

This study is being done to evaluate the relationship between adherence to antiretroviral therapy (ART) and HIV drug concentrations in persons living with HIV (PLWH) that are taking tenofovir alafenamide (TAF). Adherence will be measured with an ingestible biosensor (digital pill). Antiretroviral drug concentrations will be measured in different types of blood cells.

Conditions

Interventions

DEVICE

Digital Pill

Digital Pill over encapsulating tenofovir alafenamide ART

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Peter L Anderson, PharmD · University of Colorado-AMC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-21
Primary Completion
2023-05-16
Completion
2023-05-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04065347 on ClinicalTrials.gov